Japan Tissue Engineering Co., Ltd. announced that it submitted notification of the clinical trial plan for Allogeneic Cultured Epidermis (development name: "Allo-JaCE03") to the Pharmaceuticals and Medical Devices Agency today. J-TEC will acquire knowledge and know-how about medical devices through the development of "Allo-JaCE03" and develop new business in fields that use allogeneic cells (cells from other people). With the vision of "creating a future for regenerative medicine", J-TEC is promoting the creation of a regenerative medicine industry and contributing to the improvement of patient quality of life (QOL) by continuously developing and marketing new regenerative medical products and medical devices, in addition to promoting the spread of J-TEC's existing products. " Allo-JaCE03" is dried epidermal cell sheet derived from healthy human skin. Through reconstitution, it returns to the resilient physical properties it had before drying. Its high degree of biocompatibility makes it suitable for use in the promotion of early wound healing. Clinical Trial Summary: The purpose of this clinical trial is to verify the efficacy and confirm the safety of "Allo-JaCE03" in patients with deep dermal burn (DDB), which is a typical skin defect disorder. J-TEC plans to conduct the clinical trial at a total of 5 facilities, including Kyoto University Hospital. Product Features: Because the raw material is allogeneic cells, systematic mass-production of a product that meets certain quality standards is possible. The dried form of this cultured product means that it can be stored at room temperature for long periods of time. Medical institutions can stock it as a ready-made product (one that is manufactured and stored in advance so that it can be used without delay when needed). This product is a medical device that does not contain living cells. J-TEC is taking advantage of the product features of allogeneic origin and dried form to accelerate deployment not only within Japan but also to overseas markets.